ArticleCancer management and research2013

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel.

John C Araujo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.